Lakefront Biotherapeutics(LKFT)
$34.07-0.32 (-0.93%)
LKFT
Lakefront Biotherapeutics financials statements
$34.07
At close:-0.32 (-0.93%)
Want to see LKFT full AI Analyst Report?
Lakefront Biotherapeutics (LKFT) Ratios
549 Followers
Lakefront Biotherapeutics Ratios
LKFT's free cash flow for Q3 2026 was €-33.07M. For the 2026 fiscal year, LKFT's free cash flow was decreased by €-150.84K and operating cash flow was €-32.92M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 20.15 | 9.97 | 9.02 | 8.11 | 8.58 |
| Quick Ratio | 20.00 | 9.81 | 8.84 | 8.01 | 8.55 |
| Cash Ratio | 0.57 | 0.19 | 0.39 | 0.97 | 3.94 |
| Solvency Ratio | 2.21 | 0.10 | 0.16 | -0.07 | -0.04 |
| Operating Cash Flow Ratio | -1.68 | -0.96 | -0.95 | -0.96 | -0.89 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | € 2.91B | € 2.10B | € 2.30B | € 2.03B | € 2.31B |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 |
| Debt-to-Equity Ratio | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 |
| Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.05 | 1.43 | 1.56 | 1.87 | 1.96 |
| Debt Service Coverage Ratio | 170.31 | 49.54 | 25.04 | 0.36 | -8.92 |
| Interest Coverage Ratio | 226.16 | -206.74 | -53.36 | -14.32 | -14.29 |
| Debt to Market Cap | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.14 | 0.19 | 0.17 | 0.47 | 0.59 |
| Net Debt to EBITDA | -0.23 | -1.21 | -3.08 | -125.57 | 21.86 |
| Profitability Margins | |||||
| Gross Profit Margin | 97.33% | 87.35% | 100.00% | 100.00% | 99.66% |
| EBIT Margin | 27.25% | -0.79% | 3.08% | -25.57% | -25.21% |
| EBITDA Margin | 32.27% | 15.72% | 21.29% | 1.60% | -20.82% |
| Operating Profit Margin | 45.08% | -68.33% | -36.82% | -54.32% | -34.15% |
| Pretax Profit Margin | 27.05% | -1.12% | 2.35% | -29.37% | -25.37% |
| Net Profit Margin | 28.85% | 26.88% | 88.31% | -90.36% | -25.87% |
| Continuous Operations Profit Margin | 28.72% | -0.47% | -1.66% | -29.60% | -25.87% |
| Net Income Per EBT | 106.65% | -2401.36% | 3763.50% | 307.68% | 101.97% |
| EBT Per EBIT | 60.01% | 1.64% | -6.37% | 54.06% | 74.28% |
| Return on Assets (ROA) | 9.42% | 1.79% | 4.86% | -4.60% | -2.42% |
| Return on Equity (ROE) | 9.92% | 2.56% | 7.57% | -8.63% | -4.74% |
| Return on Capital Employed (ROCE) | 15.41% | -4.96% | -2.25% | -3.11% | -3.58% |
| Return on Invested Capital (ROIC) | 15.40% | -2.06% | 1.59% | -3.11% | -3.57% |
| Return on Tangible Assets | 9.42% | 1.90% | 5.09% | -4.82% | -2.44% |
| Earnings Yield | 17.50% | 4.22% | 8.73% | -8.01% | -3.95% |
| Efficiency Ratios | |||||
| Receivables Turnover | 20.91 | 5.81 | 3.65 | 3.12 | 3.77 |
| Payables Turnover | 0.91 | 0.36 | 0.00 | 0.00 | 0.01 |
| Inventory Turnover | 1.32 | 0.68 | 0.00 | 0.00 | 0.08 |
| Fixed Asset Turnover | 13.79 | 2.24 | 1.90 | 1.56 | 3.53 |
| Asset Turnover | 0.33 | 0.07 | 0.06 | 0.05 | 0.09 |
| Working Capital Turnover Ratio | 0.00 | 0.09 | 0.07 | 0.06 | 0.11 |
| Cash Conversion Cycle | -106.86 | -424.89 | 99.97 | 117.02 | -25387.09 |
| Days of Sales Outstanding | 17.46 | 62.87 | 99.97 | 117.02 | 96.81 |
| Days of Inventory Outstanding | 276.09 | 535.96 | 0.00 | 0.00 | 4608.77 |
| Days of Payables Outstanding | 400.41 | 1023.71 | 0.00 | 0.00 | 30092.67 |
| Operating Cycle | 293.55 | 598.82 | 99.97 | 117.02 | 4705.58 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -3.91 | -4.84 | -6.16 | -7.62 | -7.69 |
| Free Cash Flow Per Share | -4.12 | -6.08 | -6.45 | -8.18 | -8.58 |
| Dividend Paid and CapEx Coverage Ratio | -18.58 | -3.90 | -21.06 | -13.55 | -8.70 |
| Capital Expenditure Coverage Ratio | -18.58 | -3.90 | -21.06 | -13.55 | -8.70 |
| Operating Cash Flow Coverage Ratio | -37.23 | -27.30 | -42.31 | -22.85 | -18.76 |
| Operating Cash Flow to Sales Ratio | -0.23 | -1.16 | -1.69 | -2.07 | -1.04 |
| Free Cash Flow Yield | -14.79% | -22.89% | -17.54% | -19.74% | -17.69% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | 5.71 | 23.71 | 11.45 | -12.49 | -25.32 |
| Price-to-Sales (P/S) Ratio | 1.65 | 6.37 | 10.11 | 11.29 | 6.55 |
| Price-to-Book (P/B) Ratio | 0.57 | 0.61 | 0.87 | 1.08 | 1.20 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -6.76 | -4.37 | -5.70 | -5.07 | -5.65 |
| Price-to-Operating Cash Flow Ratio | -7.12 | -5.49 | -5.97 | -5.44 | -6.30 |
| Price-to-Earnings Growth (PEG) Ratio | 0.02 | -0.01 | -0.12 | -0.17 | 0.42 |
| Enterprise Value Multiple | 4.88 | 39.33 | 44.43 | 577.68 | -9.60 |
| Enterprise Value | 1.75B | 1.70B | 2.27B | 2.24B | 969.02M |
| EV to EBITDA | 4.88 | 39.33 | 44.43 | 577.68 | -9.60 |
| EV to Sales | 1.58 | 6.18 | 9.46 | 9.27 | 2.00 |
| EV to Free Cash Flow | -6.46 | -4.24 | -5.33 | -4.16 | -1.73 |
| EV to Operating Cash Flow | -6.81 | -5.32 | -5.59 | -4.47 | -1.92 |
| Tangible Book Value Per Share | 49.09 | 40.25 | 39.41 | 35.16 | 39.44 |
| Shareholders’ Equity Per Share | 49.10 | 43.80 | 42.40 | 38.45 | 40.36 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | -0.06 | 0.58 | 1.71 | -0.01 | -0.02 |
| Revenue Per Share | 16.88 | 4.17 | 3.64 | 3.67 | 7.40 |
| Net Income Per Share | 4.87 | 1.12 | 3.21 | -3.32 | -1.91 |
| Tax Burden | 1.07 | -24.01 | 37.64 | 3.08 | 1.02 |
| Interest Burden | 0.99 | 1.42 | 0.76 | 1.15 | 1.01 |
| Research & Development to Revenue | 0.41 | 1.22 | 1.01 | 1.12 | 1.01 |
| SG&A to Revenue | 0.10 | 0.35 | 0.39 | 0.42 | 0.20 |
| Stock-Based Compensation to Revenue | 0.02 | 0.00 | 0.24 | 0.37 | 0.15 |
| Income Quality | -0.80 | -4.32 | -1.92 | 2.30 | 4.88 |
Currency in EUR

